Cipla and Ranbaxy can appreciate 20% from current price levels: Deven Choksey

In a chat with ET Now, Deven Choksey, MD, KR Choksey Securities shares his view on Pharma space:

ET Now: So from 2014 perspective out of the four pharma names which is Sun Pharma, Cipla, Ranbaxy, and Lupin where do you see the maximum upside?

Deven Choksey: Cipla and Ranbaxy hold reasonably good chance of appreciating around 20% to 30% from current market price levels.

Sun Pharma definitely distinctly looks a very positive company but the fact that on the pricing front or the stock market is concerned Cipla could definitely surprise on the upside. Ranbaxy has already shown some initial moment of course with more clarity coming in it could also follow suit but if you are talking of 20-30% these are the two companies that I get confidence.

I am not sure whether Sun Pharma and Lupin could give 20-30% appreciation at least in the first half of 2014, may be we will have to wait till the second half of 2014 or may be financial year 2015.